𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Genetic testing in Parkinson's disease

✍ Scribed by Aideen McInerney-Leo; Donald W. Hadley; Katrina Gwinn-Hardy; John Hardy


Publisher
John Wiley and Sons
Year
2004
Tongue
English
Weight
94 KB
Volume
20
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Parkinson's disease (PD) is a common neurodegenerative disorder of adulthood characterized clinically by rigidity, bradykinesia, resting tremor, and postural instability. The annual incidence of PD ranges between 16 and 19 individuals per 100,000 (Twelves et al., Mov Disord 2003;18:19–31). Historically, PD has been commonly viewed as an idiopathic or environmentally triggered condition. However, as is true with most common conditions, there have been several families reported with PD who demonstrate a classic Mendelian pattern of inheritance. To date, nine genetic loci have been reported and four pathogenic genes have been identified: α‐synuclein, parkin, DJ1, and PINK1. Families with alterations in these genes or linked sites demonstrate either recessive or dominant inheritance patterns and may have typical and/or atypical symptoms, with an age of onset extending from the second to the sixth decade. Commercial tests for parkin and α‐synuclein mutations are now available. We predict that physicians, particularly neurologists, increasingly will be approached for information and referrals regarding genetic testing. To assist patients and their families, physicians will not only need to know when such testing is likely to yield a meaningful result but also be aware of the possible social and emotional consequences of testing. The following is a review of what is currently known about the genetics of PD within this context. We discuss what is known about genetic testing for Huntington's disease, a well‐described model for genetic testing in a neurodegenerative disorder. We explore the utility, appropriateness, and possible implications of genetic testing for diagnostic and presymptomatic purposes. Published 2004 John Wiley & Sons


πŸ“œ SIMILAR VOLUMES


Genetic testing in Parkinson's disease
✍ Aideen McInerney-Leo πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 65 KB

iology was found. Our case documents the occurrence of this unusual myoclonus physiology in biopsy-proven Lafora disease. Indeed, the movement disorder neurophysiology evaluation was more useful in terms of defining a myoclonus physiology than routine EEG. Wilkins and colleagues 4 first described t

Genetic testing in Huntington's disease
✍ William C. Koller; Joyce Davenport πŸ“‚ Article πŸ“… 1984 πŸ› John Wiley and Sons 🌐 English βš– 249 KB πŸ‘ 1 views
Genetics of Parkinson's disease
✍ R. C. Duvoisin πŸ“‚ Article πŸ“… 1992 πŸ› John Wiley and Sons 🌐 English βš– 59 KB
Genetics of Parkinson's disease and park
✍ John Hardy; Huaiban Cai; Mark R. Cookson; Katrina Gwinn-Hardy; Andrew Singleton πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 174 KB πŸ‘ 3 views
Timed tests in parkinson's disease evalu
✍ Anthony E. Lang; P. MartΓ­anez-MartΓ­n; D. GarcΓ­a Urra; J. Balseiro GΓ³mez πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 193 KB
Myocardial 123metaiodobenzylguanidine up
✍ Aldo Quattrone; Antonio Bagnato; Grazia Annesi; Fabiana Novellino; Letterio Morg πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 348 KB

## Abstract Myocardial ^123^Metaiodobenzylguanidine (MIBG) enables the assessment of postganglionic sympathetic cardiac innervation. MIBG uptake is decreased in nearly all patients with Parkinson's disease (PD). Our objective was to evaluate MIBG uptake in patients with genetic PD. We investigated